Moderna Inc
1MRNA
Company Profile
Business description
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Contact
325 Binney Street
CambridgeMA02142
USAT: +1 617 714-6500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
4,700
Stocks News & Analysis
stocks
What did Morningstar subscribers buy and sell during June?
ETFs took centre stage in June alongside renewed interest in beaten down growth names.
stocks
Australia’s largest gold miner downgraded on a falling gold price
A cooling gold price sees fair value cuts across the board.
stocks
Cheap ASX share pays a heavy price for NRL rights
Growth has slowed amid increased competition for viewers and content.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,001.30 | 3.70 | 0.04% |
| CAC 40 | 8,366.85 | 2.20 | 0.03% |
| DAX 40 | 25,144.38 | 30.13 | 0.12% |
| Dow JONES (US) | 52,414.61 | 84.03 | -0.16% |
| FTSE 100 | 10,529.39 | 31.10 | 0.30% |
| HKSE | 24,340.73 | 127.01 | 0.52% |
| NASDAQ | 26,112.88 | 239.71 | 0.93% |
| Nikkei 225 | 67,743.50 | 500.77 | 0.74% |
| NZX 50 Index | 13,651.22 | 71.98 | -0.52% |
| S&P 500 | 7,542.83 | 27.49 | 0.37% |
| S&P/ASX 200 | 8,808.50 | 4.80 | 0.05% |
| SSE Composite Index | 3,967.13 | 53.33 | 1.36% |